254 related articles for article (PubMed ID: 29483509)
21. Distinct inhibitory effects on mTOR signaling by ethanol and INK128 in diffuse large B-cell lymphoma.
Mazan-Mamczarz K; Peroutka RJ; Steinhardt JJ; Gidoni M; Zhang Y; Lehrmann E; Landon AL; Dai B; Houng S; Muniandy PA; Efroni S; Becker KG; Gartenhaus RB
Cell Commun Signal; 2015 Mar; 13():15. PubMed ID: 25849580
[TBL] [Abstract][Full Text] [Related]
22. Antitumor effects and mechanisms of 1,25(OH)2D3 in the Pfeiffer diffuse large B lymphoma cell line.
Han J; Tang Y; Zhong M; Wu W
Mol Med Rep; 2019 Dec; 20(6):5064-5074. PubMed ID: 31638226
[TBL] [Abstract][Full Text] [Related]
23. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
[TBL] [Abstract][Full Text] [Related]
24. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling.
Yang J; Li Y; Zhang Y; Fang X; Chen N; Zhou X; Wang X
J Exp Clin Cancer Res; 2020 Jul; 39(1):142. PubMed ID: 32711549
[TBL] [Abstract][Full Text] [Related]
25. MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma.
Lee JS; Tang SS; Ortiz V; Vo TT; Fruman DA
Oncotarget; 2015 Nov; 6(34):35202-17. PubMed ID: 26460954
[TBL] [Abstract][Full Text] [Related]
26. Role of p70S6K1-mediated phosphorylation of eIF4B and PDCD4 proteins in the regulation of protein synthesis.
Dennis MD; Jefferson LS; Kimball SR
J Biol Chem; 2012 Dec; 287(51):42890-9. PubMed ID: 23105104
[TBL] [Abstract][Full Text] [Related]
27. ROR1 associates unfavorable prognosis and promotes lymphoma growth in DLBCL by affecting PI3K/Akt/mTOR signaling pathway.
Mao Y; Xu L; Wang J; Zhang L; Hou N; Xu J; Wang L; Yang S; Chen Y; Xiong L; Zhu J; Fan W; Xu J
Biofactors; 2019 May; 45(3):416-426. PubMed ID: 30801854
[TBL] [Abstract][Full Text] [Related]
28. Helicobacter pylori promotes eukaryotic protein translation by activating phosphatidylinositol 3 kinase/mTOR.
Sokolova O; Vieth M; Gnad T; Bozko PM; Naumann M
Int J Biochem Cell Biol; 2014 Oct; 55():157-63. PubMed ID: 25194338
[TBL] [Abstract][Full Text] [Related]
29. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events.
Holz MK; Ballif BA; Gygi SP; Blenis J
Cell; 2005 Nov; 123(4):569-80. PubMed ID: 16286006
[TBL] [Abstract][Full Text] [Related]
30. Activation and up-regulation of translation initiation factor 4B contribute to arsenic-induced transformation.
Zhang Y; Wang Q; Guo X; Miller R; Guo Y; Yang HS
Mol Carcinog; 2011 Jul; 50(7):528-38. PubMed ID: 21268130
[TBL] [Abstract][Full Text] [Related]
31. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
Zhao MY; Auerbach A; D'Costa AM; Rapoport AP; Burger AM; Sausville EA; Stass SA; Jiang F; Sands AM; Aguilera N; Zhao XF
Clin Cancer Res; 2009 Mar; 15(5):1708-20. PubMed ID: 19223503
[TBL] [Abstract][Full Text] [Related]
32. New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors.
Golob-Schwarzl N; Krassnig S; Toeglhofer AM; Park YN; Gogg-Kamerer M; Vierlinger K; Schröder F; Rhee H; Schicho R; Fickert P; Haybaeck J
Eur J Cancer; 2017 Sep; 83():56-70. PubMed ID: 28715695
[TBL] [Abstract][Full Text] [Related]
33. Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival.
Wang Y; Begley M; Li Q; Huang HT; Lako A; Eck MJ; Gray NS; Mitchison TJ; Cantley LC; Zhao JJ
Proc Natl Acad Sci U S A; 2016 Aug; 113(35):9810-5. PubMed ID: 27528663
[TBL] [Abstract][Full Text] [Related]
34. Targeting ZDHHC21/FASN axis for the treatment of diffuse large B-cell lymphoma.
Liu B; Zhao X; Zhang S; Li Q; Li X; Huang D; Xia J; Ma N; Duan Y; Zhang X; Rao J
Leukemia; 2024 Feb; 38(2):351-364. PubMed ID: 38195819
[TBL] [Abstract][Full Text] [Related]
35. Intracerebroventricular administration of ouabain, a Na/K-ATPase inhibitor, activates mTOR signal pathways and protein translation in the rat frontal cortex.
Kim SH; Yu HS; Park HG; Ha K; Kim YS; Shin SY; Ahn YM
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():73-82. PubMed ID: 23643758
[TBL] [Abstract][Full Text] [Related]
36. Interferon-dependent engagement of eukaryotic initiation factor 4B via S6 kinase (S6K)- and ribosomal protein S6K-mediated signals.
Kroczynska B; Kaur S; Katsoulidis E; Majchrzak-Kita B; Sassano A; Kozma SC; Fish EN; Platanias LC
Mol Cell Biol; 2009 May; 29(10):2865-75. PubMed ID: 19289497
[TBL] [Abstract][Full Text] [Related]
37. UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma.
Bedekovics T; Hussain S; Feldman AL; Galardy PJ
Blood; 2016 Mar; 127(12):1564-74. PubMed ID: 26702068
[TBL] [Abstract][Full Text] [Related]
38. Down-regulation of PKM2 decreases FASN expression in bladder cancer cells through AKT/mTOR/SREBP-1c axis.
Tao T; Su Q; Xu S; Deng J; Zhou S; Zhuang Y; Huang Y; He C; He S; Peng M; Hocher B; Yang X
J Cell Physiol; 2019 Mar; 234(3):3088-3104. PubMed ID: 30221356
[TBL] [Abstract][Full Text] [Related]
39. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
Petrich AM; Leshchenko V; Kuo PY; Xia B; Thirukonda VK; Ulahannan N; Gordon S; Fazzari MJ; Ye BH; Sparano JA; Parekh S
Clin Cancer Res; 2012 May; 18(9):2534-44. PubMed ID: 22338016
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of B-cell intracellular signaling by monitoring the PI3K-Akt axis in patients with common variable immunodeficiency and activated phosphoinositide 3-kinase delta syndrome.
Del Pino-Molina L; Torres Canizales JM; Rodríguez-Pena R; López-Granados E
Cytometry B Clin Cytom; 2021 Jul; 100(4):460-466. PubMed ID: 32961022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]